The Food and Drug Administration is relaxing regulations on biosimilar drugs used for cancer and rare diseases in the hopes of boosting competition and lowering prices for high-cost pharmaceuticals.
LONDON (Reuters) -The mood music in some of the world's biggest bond markets has shifted in October as concerns about hefty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback